• Annals of Laboratory Medicine
• /
• 제38권6호
• /
• pp.578-584
• /
• 2018

Background: Accurate, rapid, and cost-effective screening tests for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection may be useful in laboratories that cannot afford automated chemiluminescent immunoassays (CLIAs). We evaluated the diagnostic performance of a novel rapid automated fluorescent lateral flow immunoassay (LFIA). Methods: A fluorescent LFIA using a small bench-top fluorescence reader, Automated Fluorescent Immunoassay System (AFIAS; Boditech Med Inc., Chuncheon, Korea), was developed for qualitative detection of hepatitis B surface antigen (HBsAg), antibody to HBsAg (anti-HBs), and antibody to HCV (anti-HCV) within 20 minutes. We compared the diagnostic performance of AFIAS with that of automated CLIAs-Elecsys (Roche Diagnostics GmbH, Penzberg, Germany) and ARCHITECT (Abbott Laboratories, Abbott Park, IL, USA)-using 20 seroconversion panels and 3,500 clinical serum samples. Results: Evaluation with the seroconversion panels demonstrated that AFIAS had adequate sensitivity for HBsAg and anti-HCV detection. From the clinical samples, AFIAS sensitivity and specificity were 99.8% and 99.3% for the HBsAg test, 100.0% and 100.0% for the anti-HBs test, and 98.8% and 99.1% for the anti-HCV test, respectively. Its agreement rates with the Elecsys HBsAg, anti-HBs, and anti-HCV detection assays were 99.4%, 100.0%, and 99.0%, respectively. AFIAS detected all samples with HBsAg genotypes A-F and H and anti-HCV genotypes 1, 1a, 1b, 2a, 2b, 4, and 6. Cross-reactivity with other infections was not observed. Conclusions: The AFIAS HBsAg, anti-HBs, and anti-HCV tests demonstrated diagnostic performance equivalent to current automated CLIAs. AFIAS could be used for a large-scale HBV or HCV screening in low-resource laboratories or low-to middle-income areas.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권4호
• /
• pp.2145-2150
• /
• 2016

Background: Infection with hepatitis B virus (HBV) is a major global public health problem, with a wide spectrum of clinical manifestations. Human cytosolic glutathione-S-transferases (GSTs) include several classes such as alpha (A), mu (M), pi (P), sigma (S), zeta (Z), omega (O) and theta (T). The present study aimed to investigate the role of GST omega genes (GSTO1 and GSTO2) in different groups of patients infected with HBV. Materials and Methods: HBV groups were classified according to clinical history, serological tests and histological analysis into normal carriers (N), acute (A), chronic (CH), cirrhosis (CI) and hepatocellular carcinoma (HCC) cases. The study focused on determination of the genotypes of GST omega genes (GSTO1 and GSTO2) and GST activity and liver function tests. Results: The results showed that GSTO1 (A/A) was decreased in N, A, CH, CI and HCC groups compared to the C-group, while, GSTO1 (C/A) and GSTO1(C/C) genotypes were increased significantly in N, A, CH, CI and HCC groups. GSTO2 (A/A) was decreased in all studied groups as compared to the C-group but GSTO2(A/G) and GSTO2(G/G) genotypes were increased significantly. In addition, GST activities, albumin and TP levels were decreased in all studied groups compared to the C-group, while the activities of transaminases were increased to differing degrees. Conclusions: The results indicate that GSTO genetic polymorphisms may be considered as biomarkers for determining and predicting the progression of HBV infection.

• IMMUNE NETWORK
• /
• 제13권1호
• /
• pp.25-29
• /
• 2013

Ribavirin is an antiviral drug used in combination with pegylated interferon-${\alpha}$ (IFN-${\alpha}$) for the treatment of hepatitis C virus (HCV) infection. Recently, ribavirin was reported to inhibit the suppressive activity of regulatory T (Treg) cells. In the present study, we re-evaluated the effect of ribavirin on $CD4^+$ $CD4^+$ $CD25^+$ Treg cells from normal donors. First, we examined the expression of CTLA-4 and CD39, which are known to play a role in the suppressive function of Treg cells. We found that ribavirin treatment did not modulate the expression of CTLA-4 and CD39 in Treg cells. We also studied the effect of ribavirin on Treg cells in the presence of IFN-${\alpha}$; however, the expression of CTLA-4 and CD39 in Treg cells was not changed by ribavirin in the presence of IFN-${\alpha}$. Next, we directly evaluated the effect of ribavirin on the suppressive activity of Treg cells in the standard Treg suppression assay, by co-culturing CFSE-labeled non-Treg $CD4^+$ T cells with purified Treg cells. We found that ribavirin did not attenuate the suppressive activity of Treg cells. Taken together, while ribavirin reversed Treg cell-mediated suppression of effector T cells in the previous study, we herein demonstrate that ribavirin does not impair the suppressive activity of Treg cells.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제4권2호
• /
• pp.207-212
• /
• 2001

목적: Mycoplasma pneumoniae 폐렴은 소아과 영역에서 비교적 흔한 질환인데 동반되는 다양한 폐외 소견에 대해서는 많은 보고들이 있었으나 간염에 대해서는 연구된 바가 적으며 특히 국내에서는 이에 대한 연구가 아직 없는 실정이다. 따라서 저자들은 M. pneumoniae에 의한 간염의 전반적인 임상적 특성들을 조사하여 보고하고자 한다. 방법: 1999년 1월 1일부터 2000년 12월 31일까지 서울적십자병원 소아과에 입원한 143명의 마이코플라스마 폐렴 환아들 중 AST와 ALT 수치가 각각 50 IU/L 이상 증가된 환아로서 hepatitis A, B, C 및 cytomegalovirus와 Ebstein-Barr virus가 음성인 19명을 대상으로 계절 분포, 연령 및 성별 분포, 주요 임상증상 및 이학적 소견, 혈액학적 검사, 간기능 검사, 방사선학적 검사, 재원기간, 회복기간 등을 전향적으로 조사하였다. 결과: 1) 마이코플라스마 감염 중 13.3%에서 발생하였으며 가을과 겨울에 호발하였고 평균연령은 4.86세였고 남녀비는 2.2 대 1이었다. 2) 소화기 증상들 중 구토는 21.1%, 설사는 36.8%이었으며 간종대는 21.1%에서 관찰되었고 비장종대는 한 명에서도 관찰되지 않았다. 3) 백혈구가 $10,000/mm^3$이상으로 증가된 경우는 21.1%이었으며 $4,000/mm^3$ 미만으로 감소된 경우는 없었고 호산구증이 15.4%에서 나타났다. 혈색소가 10 g/dl 이하로 감소된 경우는 10.5%이었으며 혈소판이 $450,000/mm^3$ 이상으로 증가된 경우는 5.3%이었고 $150,000/mm^3$ 미만으로 감소된 경우는 없었다. C-반응성 단백은 0.5 mg/dl 이하가 15.4%이었으며 가장 높은 수치는 16.2 mg/dl이었고 평균 $6.34{\pm}4.82$ mg/dl였다. 4) 고빌리루빈혈증을 보인 경우는 없었으며 알부민이 3.5 g/dl 미만으로 감소된 경우는 42.1%이었다. AST의 평균은 $214.05{\pm}183.22$ IU/L였으며 가장 증가된 경우는 630 IU/L였고 ALT의 평균은 $284.16{\pm}286.84$ IU/L였으며 가장 증가된 경우는 1,089 IU/L였다. 5) 흉부 방사선 쵤영상 대엽성 또는 소엽성 형태로 폐침윤을 보인 경우는 73.7%이었고 기관지성 형태의 폐침윤을 보인 경우는 26.3%이었으며 흉막삼출액은 31.6%에서 나타났다. 6) 재원 기간은 평균 7.9일이었으며 간기능 회복 시기는 평균 8.8일 이내였고 모든 환아에서 2주 이내에 간기능이 완전히 정상으로 회복되었다. 결론: Mycoplasma pneumoniae 간염은 대부분 2주 이내에 회복되는 양성 경과를 취하나 그 빈도가 낮지 않으므로 마이코플라스마 폐렴시 간기능 검사 소견에 주의를 기울여야 한다.

• 미생물학회지
• /
• 제47권4호
• /
• pp.342-347
• /
• 2011

인체의 바이러스 감염 방어기전에서 T 림프구는 중요한 역할을 한다. 하지만, 만성 C형 간염 바이러스의 일차적 복제장소인 간염 환자의 간에서 분리된 HCV 특이 T 림프구는 심각한 기능결핍을 보인다. 이러한 T 림프구 기능결핍의 이유로는 PD-1, CTLA-4 등 면역억제 물질의 발현, 또는 간에서 특이적으로 유도되는 면역내성(immune tolerance)이 있으나, 간세포(hepatocytes)와 HCV 특이 T 림프구의 상호작용에 대해서는 명확하게 확립되어 있지 않다. 따라서 본 연구에서는 HLA(human leukocyte antigen) A2+ 간암세포주(human hepatoma cell line; huh7.5)가 항원제시(antigen presentation)를 통해 효과적으로 HCV 특이 T 림프구를 활성화시키며 간암세포주(huh7.5) 표면의 PD-L (program death ligand) 1 발현은 T림프구의 활성을 감소시켜 면역조절의 가능성이 있음을 시사하였다. 또한, HCV 특이 tetramer 반응은 T 림프구의 과도한 활성으로 자기사멸(apoptosis)의 경로에 있음을 caspase 3 활성으로 확인하였고, 역시 PD-L1의 발현이 T 림프구를 자기사멸(apoptosis)로부터 구제하여 caspase 3 활성이 감소하는 것을 확인하였다. 이는 PD-L1과 간성(liver) T 림프구 표면의 PD-1 결합이 T 림프구의 자기사멸을 막고, 또한 그 기능을 회복시켜 만성 C형 간염 치료에 응용될 수 있음을 시사한다.

• Pediatric Infection and Vaccine
• /
• 제16권1호
• /
• pp.6-12
• /
• 2009

There are relatively few novel antimicrobial agents despite the dramatic increase in antimicrobial resistance and multiple drug resistance of clinical isolates worldwide. Vancomycin is still the most widely used antibiotic for treating resistant Gram-positive coccal infections in children, especially for methicillin-resistant Staphylococcus aureus. For children with Gram-positive coccal infections where vancomycin is not effective or older therapeutic agents cannot be tolerated, linezolid, quinupristin-dalfopristin or daptomycin may be useful in the appropriate clinical setting. For Gram-negative bacterial infections, new carbapenems await clinical application. Tebipenem pivoxil is a novel oral carbapenem undergoing clinical trials for acute otitis media in pediatric patients. Antiviral drug development is now progressing at the pace of antibiotic development 30 years ago. Newer antiviral agents used for the treatment of herpes viruses and hepatitis C virus infections in children are included in this review.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제28권4호
• /
• pp.365-370
• /
• 2006

Viral, bacterial and fungal infections can be transmitted via allografts such as bone, skin, cornea and cardiovascular tissues. Allogenic bone grafts have possibility of transmission of hepatitis C, human immunodeficiency virus (HIV-1), human T-Cell leukaemia virus (HTLV), tuberculosis and other bacterias. The tissue bank should have a policy for obtaining information from the patient's medical report as to whether the donor had risk factors for infectious diseases. Over the past several years, improvements in donor screening criteria, such as excluding potential donor with "high risk" for HIV-1 and hepatitis infection, and donor blood testing result in the reduction of transmission of these diseases. During tissue processing, many allografts are exposed to antibiotics, disinfectants and terminal sterilization such as irradiation, which further reduce or remove the risk of transmitting diseases. Because the effectiveness of some tissue grafts such as, fresh frozen osteochondral grafts, depends on cellular viability, not all can be subjected to sterilization and processing steps and, therefore, the risk of transmission of infectious disease remains. This article is review of the transmission of considering infectious disease in allogenic bone transplantation and the processing steps of reducing the risk. The risk of viral transmission in allografts can be reduced in several standards. The most important are donor-screening tests and the removal of blood and soft tissues by processing steps under the aseptic environment. In conclusion, final sterilizations including the irradiation, can be establish the safety of allografts.

• Biomolecules & Therapeutics
• /
• 제29권3호
• /
• pp.331-341
• /
• 2021

Liver cancer is a common tumor and currently the second leading cause of cancer-related mortality globally. Liver cancer is highly related to inflammation as more than 90% of liver cancer arises in the context of hepatic inflammation, such as hepatitis B virus and hepatitis C virus infection. Despite significant improvements in the therapeutic modalities for liver cancer, patient prognosis is not satisfactory due to the limited efficacy of current drug therapies in anti-metastatic activity. Therefore, developing new effective anti-cancer agents with anti-metastatic activity is important for the treatment of liver cancer. In this study, SP-8356, a verbenone derivative with anti-inflammatory activity, was investigated for its effect on the growth and migration of liver cancer cells. Our findings demonstrated that SP-8356 inhibits the proliferation of liver cancer cells by inducing apoptosis and suppressing the mobility and invasion ability of liver cancer cells. Functional studies revealed that SP-8356 inhibits the mitogen-activated protein kinase and nuclear factor-kappa B signaling pathways, which are related to cell proliferation and metastasis, resulting in the downregulation of metastasis-related genes. Moreover, using an orthotopic liver cancer model, tumor growth was significantly decreased following treatment with SP-8356. Thus, this study suggests that SP-8356 may be a potential agent for the treatment of liver cancer with multimodal regulation.

• Parasites, Hosts and Diseases
• /
• 제56권1호
• /
• pp.61-70
• /
• 2018

We developed a Rapid Diagnostic Test (RDT) kit for detecting IgG/IgM antibodies against Zika virus (ZIKV) using monoclonal antibodies to the envelope (E) and non-structural protein 1 (NS1) of ZIKV. These proteins were produced using baculovirus expression vector with Sf9 cells. Monoclonal antibodies J2G7 to NS1 and J5E1 to E protein were selected and conjugated with colloidal gold to produce the Zika IgG/IgM RDT kit (Zika RDT). Comparisons with ELISA, plaque reduction neutralization test (PRNT), and PCR were done to investigate the analytical sensitivity of Zika RDT, which resulted in 100% identical results. Sensitivity and specificity of Zika RDT in a field test was determined using positive and negative samples from Brazil and Korea. The diagnostic accuracy of Zika RDT was fairly high; sensitivity and specificity for IgG was 99.0 and 99.3%, respectively, while for IgM it was 96.7 and 98.7%, respectively. Cross reaction with dengue virus was evaluated using anti-Dengue Mixed Titer Performance Panel (PVD201), in which the Zika RDT showed cross-reactions with DENV in 16.7% and 5.6% in IgG and IgM, respectively. Cross reactions were not observed with West Nile, yellow fever, and hepatitis C virus infected sera. Zika RDT kit is very simple to use, rapid to assay, and very sensitive, and highly specific. Therefore, it would serve as a choice of method for point-of-care diagnosis and large scale surveys of ZIKV infection under clinical or field conditions worldwide in endemic areas.

• 생명과학회지
• /
• 제15권1호
• /
• pp.38-44
• /
• 2005

B형 간염 바이러스(HBV)에 의한 감염은 인류의 보건에 대단히 중요한 문제이며, 따라서 HBV에 대한 많은 연구가 수행되어져 왔다. 그러나 HBV 연구에 있어서의 주된 장애요인은 그 감염이 사람과 일부 영장류에 국한된다는 점이다. 본 연구에서는 마우스 간암 세포주인 Hepa-1c1c7 세포를 이용하여 HBV의 감염성 및 그에 따른 염증성 사이토카인인 TNF-a의 발현의 변화를 측정하였다. HBV의 표면항원(HBsAg)분비는 microparticle enzyme immunoassay를 사용하여 측정하였고, TNF-a mRNA 발현 측정에는 quantitative competitive RT-PCR 방법을 사용하였다. HBV 발현 벡터를 Hepa-1clc7 세포에 도입시켰을 경우뿐만 아니라 HBV 비리온을 갖고 있는 혈청을 사용하여 Hepa-lc1c7 세포를 감염시켰을 때에도 HBV mRNA 발현 및 HBsAg 분비가 측정되었다. 또한 두 상황 모두에서 TNF-a mRNA발현이 증가됨을 알 수 있었다. 이러한 결과는 사람과 영장류에 특이적인 HBV가 마우스 간암 세포주인 Hepa-lclc7 세포도 감염시킬 수 있다는 가능성을 제시한다. 또한 마우스 기원의 Hepa-lclc7 세포에서도 HBV의 유전자 발현에 필요한 여러 인자들이 존재하며, TNF-a와 같은 사이토카인 유전자 발현을 조절하는 세포 내 기전에 HBV가 영향을 미친다고 할 수 있다. 따라서 마우스 간암 세포주인 Hepa-lclc7 세포는 HBV 연구를 위한 시험 관내 모델로서 사용되어질 수 있을 것으로 보인다.